Table 3 |
|||
|
Health benefits and costs for metformin and the combination of metformin with nateglinide |
|||
| Metformin |
Combination |
Difference |
|
|
|
|||
| Cumulative cost (mean per patient) |
|||
| Complications |
£3,548 |
£3,084 |
£-464 |
| Total |
£5,093 |
£7,159 |
£2,066 |
| Survival (mean, years) |
|||
| Life years (discounted) |
13.5 (11.7) |
13.9 (12.1) |
0.39 (0.32) |
| Quality Adjusted (discounted) |
12.2 (10.7) |
12.6 (11.0) |
0.46 (0.37) |
| Cost-effectiveness |
|||
| Cost per LYG (discounted LYG) |
£5,403 (6,772) |
||
| Cost per QALY (discounted QALY) |
£4,500 (5,609) |
||
|
|
|||
|
LYG = Life Year Gained QALY = Quality Adjusted Life Year |
|||
|
Ward et al. Cost Effectiveness and Resource Allocation 2004 2:2 doi:10.1186/1478-7547-2-2 |
|||
